Oncology · Medical Literature
TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors.
Abstract
Tenosynovial giant cell tumors (TGCT) are rare, locally aggressive neoplasms causing pain, stiffness, swelling, limited range of motion, and joint degeneration, which can be debilitating. Therapeutic options include surgery or systemic therapy with colony-stimulating factor 1 receptor (CSF-1R) pathway inhibitors. However, many are not amenable to surgery or have high postsurgical recurrence rates. Available systemic therapies require long-term administration and can have burdensome side effects. Emactuzumab is a novel, potent, CSF-1R inhibiting monoclonal antibody with a unique mechanism of action targeting the receptor dimerization interface of the CSF-1R to reduce tumor-associated macrophages and inflammation within the TGCT microenvironment. It is the only short-course, intravenous therapy in development for TGCT. In a phase I study, emactuzumab resulted in robust and durable responses, and a manageable safety profile in patients with TGCT, supporting further research as a treatment option to address unmet need and improve quality of life in patients with TGCT. TANGENT is a randomized, double-blind, global, phase III study (NCT05417789) to investigate the safety and efficacy of intravenous emactuzumab versus placebo in patients with TGCT not amenable to surgery.Clinical trial registration: www.clinicaltrials.gov identifier is NCT05417789 initially registered on 1 June 2022.
Clinical relevance
In adult patients with biopsy-confirmed localized or diffuse TGCT who are not amenable to surgery, does short-course intravenous emactuzumab (a CSF-1R–inhibiting monoclonal antibody) improve objective tumor response rate and patient-relevant functional outcomes compared with placebo at 6 months? __SNAPSHOT__ {"studyDesign":"Phase III, randomized, double-blind, placebo-controlled trial (design/protocol publication; efficacy data from press release only — full peer-reviewed results not yet published at time of summary)","setting":"Global, multicenter (48 sites across multiple countries including the United States, France, Germany, Italy, Spain, United Kingdom, Japan, Australia, Brazil, and others)","sampleSize":"Approximately n=130 (intervention: ~87 emactuzumab, ~43 placebo; 2:1 allocation; exact final enrollment not reported in the design paper)","population":"Adults with biopsy-confirmed localized or diffuse TGCT in whom surgical resection is not appropriate due to anticipated worsening of functional limitations, high risk of early recurrence, or other surgery-related morbidity; measurable disease (longest diameter ≥20 mm); prior CSF-1/CSF-1R–targeted or TKI therapy permitted with adequate washout (≥3 months)","intervention":"Emactuzumab 1000 mg IV every 2 weeks for 5 doses over 8–10 weeks (Part 1), followed by a 3-month observation period (Part 1 total: 24 weeks); eligible patients may receive open-label retreatment or continue follow-up in Part 2 (up to 24 months post-randomization)","comparator":"Matching placebo IV on the same schedule; placebo-arm patients with disease worsening in Part 2 may crossover to open-label emactuzumab","primaryOutcome":"Objective Response Rate (ORR) at 6 months assessed by MRI per RECIST v1.1","followUp":"Part 1: 24 weeks; Part 2: follow-up to 24 months from randomization","fundingSource":"Industry (SynOx Therapeutics; originally in-licensed from Roche/Genentech)"}
Key findings
The TANGENT study design paper (PMID 42473802, Future Oncology 2026) is a protocol/design publication; quantitative efficacy results (ORR, confidence intervals, p-values, effect sizes, NNT) are not reported within the abstract provided. Per a company press release issued April 13, 2026, the trial reportedly met its primary endpoint (ORR by RECIST v1.1 at 6 months) and all key secondary endpoints with 'a high level of statistical significance' versus placebo, including Tumor Volume Score (TVS), PROMIS-PF TGCT T-score, range of motion, pain, stiffness, and quality of life. No specific ORR percentages, confidence intervals, p-values, or NNT values from the Phase 3 results are available in peer-reviewed form at this time. Supporting Phase I data (Cassier et al., EJC 2020) demonstrated ORR of 71% at end of treatment, 70% at 1 year, and 64% at 2 years across all dose levels; Phase I adverse events were predominantly grade 1/2 and included pruritus (70%), asthenia (62%), and facial edema (49%). Emactuzumab received FDA Fast Track Designation in April 2025 and EMA Orphan Drug Designation in March 2022. A BLA submission to the FDA and subsequent EU MAA are planned for the second half of 2026.
Practice implications
This publication describes the design and rationale of the TANGENT Phase III trial rather than reporting its final efficacy results; only the abstract was available for this summary, and full peer-reviewed Phase 3 outcome data have not yet been published. TGCT represents a rare, non-life-threatening but debilitating disease with meaningful unmet need — particularly for patients with diffuse disease, high recurrence risk after surgery, or those for whom resection carries prohibitive functional morbidity. Emactuzumab's mechanism (targeting the CSF-1R dimerization interface to deplete tumor-associated M2-like macrophages) is biologically rational for this CSF-1–driven tumor. Its short-course fixed regimen (5 IV doses) is a clinically meaningful differentiator from currently approved oral CSF-1R inhibitors (e.g., pexidartinib) that require continuous daily administration and carry hepatotoxicity risk. Topline press release data appear encouraging, but the absence of peer-reviewed Phase 3 results with reported effect sizes, confidence intervals, and detailed safety data precludes definitive conclusions about the magnitude of clinical benefit or comparative safety. Until full results are published and independently reviewed, emactuzumab cannot yet be incorporated into routine clinical practice. Patients least represented by this trial include those with life-threatening systemic disease, pediatric patients, and those with prior significant hepatic disease. __LIMITATIONS__ This is a protocol/design publication — full Phase 3 efficacy and safety data are available only via an unaudited press release, not peer-reviewed literature; all Phase 3 numerical results must therefore be treated as preliminary.,Relatively small sample size (~130 patients) is expected for an orphan disease but limits statistical power for subgroup analyses (e.g., localized vs. diffuse, prior TKI use).,Industry-sponsored study (SynOx Therapeutics) with several authors reporting full employment by the sponsor; potential for publication bias and selective outcome reporting.,ORR by RECIST v1.1 is a radiographic surrogate endpoint; whether tumor shrinkage translates to durable functional improvement and joint preservation over years remains to be established from the Part 2 follow-up data.,Crossover design in Part 2 (placebo patients may receive emactuzumab upon worsening) may confound long-term follow-up comparisons.,Generalizability is uncertain for patients with prior CSF-1R inhibitor failure, pediatric TGCT, or anatomical sites other than the knee/hip/ankle.,Duration of response and need for retreatment beyond the initial short course are not yet fully characterized from Phase 3 data.,Phase I safety data (pruritus 70%, asthenia 62%, facial edema 49%) were from a different dosing schedule; whether the Phase 3 fixed 1000 mg Q2W × 5 regimen replicates this profile requires confirmation in the full safety report. __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ TANGENT is a well-designed global Phase III RCT evaluating a novel, short-course IV CSF-1R inhibitor (emactuzumab) in surgically unresectable TGCT, a disease with limited therapeutic alternatives. Topline data announced by the sponsor indicate that primary and secondary endpoints were met with statistical significance versus placebo, and a BLA submission to the FDA is planned for late 2026. Clinicians should await full peer-reviewed publication with complete efficacy and safety data before incorporating emactuzumab into practice, but the emerging evidence positions it as a potentially important addition to the TGCT therapeutic armamentarium.